3,6′-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation

Journal of Neuroscience Research

Volumn 91, Issue 5, 2013, Pages 671-680

  Yoon, Jeong Seon ^a   Lee, Jong Hwan ^b   Tweedie, David ^a   Mughal, Mohamed R ^a   Chigurupati, Srinivasulu ^a   Greig, Nigel H ^a   Mattson, Mark P ^a,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Konkuk University   (South Korea)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ICAM 1; Inflammation; Ischemia; Microglia; Neuroprotection; Occlusion; Stroke; Thalidomide; TNF

Indexed keywords

3,6' DITHIOTHALIDOMIDE; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; OCCLUDIN; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; 3,6'-DITHIOTHALIDOMIDE; ANTIINFLAMMATORY AGENT; CYTOKINE; DRUG DERIVATIVE; GLIAL FIBRILLARY ACIDIC PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 3; MYELOPOIETIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; MACROPHAGE; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; BRAIN INFARCTION; C57BL MOUSE; CELL DEATH; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENCEPHALITIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NICK END LABELING; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; BRAIN INFARCTION; CELL DEATH; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GRANULOCYTE COLONY-STIMULATING FACTOR; IN SITU NICK-END LABELING; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-3; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHIL INFILTRATION; NEUTROPHILS; NITRIC OXIDE SYNTHASE TYPE II; RECOMBINANT FUSION PROTEINS; STROKE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874790917     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23190     Document Type: Article

References (55)

1. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. 2012. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7: e30275.
2. Arumugam TV, Tang SC, Lathia JD, et al. 2007. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 104: 14104-14109.
3. Baratz R, Tweedie D, Rubovitch V, et al. 2011. Tumor necrosis factor-α synthesis inhibitor, 3, 6′-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem 118: 1032-1042.
4. 2+ accumulation. Proc Natl Acad Sci U S A 92: 9328-9332.
5. Belarbi K, Jopson T, Tweedie D, et al. 2012. TNF-α protein synthesis inhibitor restores neuronal function and reverse cognitive deficits induced chronic neuroinflammation. J Neuroinflamm 9: 23.
6. Borlongan CV, Yamamoto M, Takei N, Kumazaki M, Ungsuparkorn C, Hida H, Sanberg PR, Nishino H. 2000. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 14: 1307-1317.
7. Breckwoldt MO, Chen JW, Stangenberg L, Aikawa E, Rodriguez E, Qiu S, Moskowitz MA, Weissleder R. 2008. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A 105: 18584-18589.
8. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, Mattson MP. 1996. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 2: 788-794.
9. Buttini M, Sauter A, Boddeke HW. 1994. Induction of interleukin-1 beta mRNA after focal cerebral ischemia in the rat. Brain Res Mol Brain Res 23: 126-134.
10. Canugovi C, Yoon JS, Feldman N, et al. 2012. Endonuclease 8-like 1 promotes short-term spatial memory retention and protects from ischemic stroke induced death and brain dysfunction in mice. Proc Natl Acad Sci U S A [E-pub ahead of print].
11. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, Maudsley S. 2008. Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 31: 504-511.
12. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. 2000. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10: 95-112.
13. Denes A, Thornton P, Rothwell NJ, et al. 2010. Inflammation and brain injury: acute cerebral ischemia, peripheral and central inflammation. Brain Behav Immun 24: 708-723.
14. Dobbie MS, Hurst RD, Klein NJ, Surtees RA. 1999. Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an in vitro model of the blood-brain barrier. Brain Res 830: 330-336.
15. Esposito E, Cuzzocrea S. 2011. Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 32: 107-115.
16. Fernández-López D, Faustino J, Daneman R, Zhou L, Lee SY, Derugin N, Wendland MF, Vexler ZS. 2012. Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. JNeurosci 32: 9588-9600.
17. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. 2002. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22: RC216.
18. Gabbita SP, Srivastava MK, Eslami P, et al. 2012. Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflamm 9: 99.
19. Gidday JM, Gasche YG, Copin JC, et al. 2005. Leukocyte-derived matrix metalloproteinsase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 289: H558-H568.
20. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. 2005. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54: 540-545.
21. Greig NH, Giordano T, Zhu X, Yu QS, Perry TA, Holloway HW, Brossi A, Rogers JT, Sambamurti K, Lahiri DK. 2004. Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiol Exp 64: 1-9.
22. He P, Liu Q, Wu J, Shen Y. 2012. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J 26: 334-345.
23. Iadecola C, Zhang F, Xu S, et al. 1995. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 15: 378-384.
24. Laffitte E, Revuz J. 2004. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 3: 47-56.
25. Lambertsen KL, Biber K, Finsen B. 2012. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2012.88 [E-pub ahead of print].
26. Liu T, Clark RK, McDonnell PC, et al. 1994. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 25: 1481-1488.
27. Liu W, Hendren J, Qin XJ, et al. 2009. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 108: 811-820.
28. Mattson MP. 2003. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 3: 65-94.
29. Mayhan WG. 2002. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res 927: 144-152.
30. McColl BW, Rothwell NJ, Allan SM. 2008. Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. Neurobiol Dis 28: 9451-9462.
31. Michaluk P, Kaczmarek L. 2007. Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ 14: 1255-1258.
32. Offner H, Subrammanian S, Parker SM, et al. 2006. Experimental stroke induces massive, rapid activation of peripheral immune system. J Cereb Blood Flow Metab 26: 654-665.
33. Ordás I, Mould DR, Feagan BG, Sandborn WJ. 2012. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91: 635-646.
34. Ossandon A, Cassarà EA, Priori R, Valesini G. 2002. Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol 20: 709-718.
35. Pan W, Kastin A. 2007. Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol 83: 363-374.
36. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. 2011. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Invest Drugs 20: 1555-1564.
37. Roger VL, Go AS, Lloyd-Jones DM, et al. 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
38. Romanic AM, White RF, Arleth AJ, et al. 1998. Matrix metalloproteinases expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29: 1020-2030.
39. Rosell A, Cuadrado E, Ortega-Aznar A, et al. 2008. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39: 1121-1126.
40. Rosenberg GA. 1999. Ischemic brain edema. Prog Cardiovasc Dis 42: 209-216.
41. Ryu JK, Jantaratnotai N, McLarnon JG. 2009. Thalidomide inhibition of vascular remodeling and inflammatory reactivity in the quinolinic acid-injected rat striatum. Neuroscience 163: 601-608.
42. Shah IM, Macrae IM, Napoli DI. 2009. Neuroinflammation and neuroprotective strategies in acute ischaemic stroke-from bench to bedside. Curr Mol Med 9: 336-354.
43. Siesjo BK, Siesjo P. 1996. Mechanisms of secondary brain injury. Eur J Anaesthesiol 13: 247-268.
44. Stanimirovic D, Satoh K. 2000. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol 10: 113-126.
45. Swanson RA, Sharp FR. 1994. Infarct measurement methodology. J Cereb Blood Flow Metab 14: 697-698.
46. Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T, Wakigawa T, Harada E, Miyaji H, Koga M, Nishioku T, Yamauchi A, Kataoka Y. 2011. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflamm 8: 106.
47. Tang SC, Arumugam TV, Xu X, et al. 2007. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 104: 13798-13803.
48. Tuttolomondo A, Raimondo DD, Sciacca RD, et al. 2008. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 14: 3574-3589.
49. Tweedie D, Luo W, Short RG, Brossi A, Holloway HW, Li Y, Yu QS, Greig NH. 2009. A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. J Neurosci Methods 183: 182-187.
50. Tweedie D, Ferguson RA, Fishman K, et al. 2012. Tumor necrosis factor-α synthesis inhibitor 3, 6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflamm 9: 106.
51. Wang Q, Tang XN, Yenari MA. 2007. The inflammatory response in stroke. J Neuroimmunol 184: 53-68.
52. Yilmaz G, Granger DN. 2010. Leukocyte recruitment and ischemic brain injury. Neuromol Med 12: 193-204.
53. Zhao BQ, Wang A, Kim HY, et al. 2006. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 4: 441-445.
54. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351.
55. Zhu X, Giordano T, Yu Q, et al. 2003. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem 46: 5222-5229.